These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7897410)

  • 1. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.
    Trojano M; Avolio C; Manzari C; Calò A; De Robertis F; Serio G; Livrea P
    J Neurol Neurosurg Psychiatry; 1995 Mar; 58(3):300-6. PubMed ID: 7897410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European validation of a standardized clinical description of multiple sclerosis.
    Amato MP; Grimaud J; Achiti I; Bartolozzi ML; Adeleine P; Hartung HP; Kappos L; Thompson A; Trojano M; Vukusic S; Confavreux C;
    J Neurol; 2004 Dec; 251(12):1472-80. PubMed ID: 15645346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for survival in multiple sclerosis.
    Lević ZM; Dujmović I; Pekmezović T; Jarebinski M; Marinković J; Stojsavljević N; Drulović J
    Mult Scler; 1999 Jun; 5(3):171-8. PubMed ID: 10408717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials.
    Amato MP; Ponziani G; Bartolozzi ML; Siracusa G
    J Neurol Sci; 1999 Oct; 168(2):96-106. PubMed ID: 10526190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
    Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
    Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for early severity in a childhood multiple sclerosis cohort.
    Mikaeloff Y; Caridade G; Assi S; Suissa S; Tardieu M
    Pediatrics; 2006 Sep; 118(3):1133-9. PubMed ID: 16951008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kurtzke scales revisited: the application of psychometric methods to clinical intuition.
    Hobart J; Freeman J; Thompson A
    Brain; 2000 May; 123 ( Pt 5)():1027-40. PubMed ID: 10775547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course and prognosis in early-onset MS: comparison with adult-onset forms.
    Simone IL; Carrara D; Tortorella C; Liguori M; Lepore V; Pellegrini F; Bellacosa A; Ceccarelli A; Pavone I; Livrea P
    Neurology; 2002 Dec; 59(12):1922-8. PubMed ID: 12499484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study on the prognosis of multiple sclerosis.
    Amato MP; Ponziani G
    Neurol Sci; 2000; 21(4 Suppl 2):S831-8. PubMed ID: 11205358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of multiple sclerosis with early onset.
    Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M
    Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension.
    Myhr KM; Riise T; Vedeler C; Nortvedt MW; Grønning R; Midgard R; Nyland HI
    Mult Scler; 2001 Feb; 7(1):59-65. PubMed ID: 11321195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).
    Kantarci O; Siva A; Eraksoy M; Karabudak R; Sütlaş N; Ağaoğlu J; Turan F; Ozmenoğlu M; Toğrul E; Demirkiran M
    Neurology; 1998 Sep; 51(3):765-72. PubMed ID: 9748024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.
    Hawkins SA; McDonnell GV
    J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):148-52. PubMed ID: 10406979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.